Major Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Depressive DisordersKetamine

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

This review (2015) discusses research developments regarding therapeutic compounds that exert their antidepressant efficacy via the glutamatergic, cholinergic, and opioid systems. The authors encourage innovative research strategies for improving the efficacy of treatments such as ketamine, whose effects are rapid but not long-lasting.

Authors

  • Daniel Ionescu
  • George Papakostas

Published

Molecular Psychiatry
meta Study

Abstract

Review: Depression is a devastating disorder that places a significant burden on both the individual and society. As such, the discovery of novel therapeutics and innovative treatments-especially for treatment-resistant depression (TRD)-are essential. Research into antidepressant therapies for TRD has evolved from explorations of antidepressants with primary mechanisms of action on the monoaminergic neurotransmitter system to augmentation agents with primary mechanisms both within and outside of the serotonin/norepinephrine system. Now the field of antidepressant research has changed trajectories yet again; this time, compounds with primary mechanisms of action on the glutamatergic, cholinergic and opioid systems are in the forefront of antidepressant exploration. In this review, we will discuss the most recent research surrounding these novel compounds. In addition, we will discuss novel device-based therapeutics, with a particular focus on transcranial magnetic stimulation. In many cases of antidepressant drug discovery, the role of serendipity coupled with meticulous clinical observation in drug development in medicine was crucial. Moving forward, we must look toward the combination of innovation plus improvements on the remarkable discoveries thus far to advance the field of antidepressant research.

Available with Blossom Pro

Research Summary of 'Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder'

Introduction

Depression is described as a highly burdensome, pervasive disorder for which a large proportion of patients do not achieve adequate benefit from standard treatments. The paper focuses on treatment-resistant depression (TRD), operationalised in the text as failure to achieve response to one or more adequate antidepressant trials, and highlights that, after decades of monoaminergic drug development, many patients remain symptomatic and therefore require new therapeutic strategies. Papakostas outlines a shift in research trajectories away from sole reliance on monoaminergic mechanisms towards agents acting on glutamatergic, cholinergic and opioid systems, as well as device-based and procedural therapies. The review updates an earlier overview of TRD from roughly five years prior, organising the discussion by drug class and addressing both pharmacological and device interventions with an emphasis on novel and rapidly acting approaches.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (5)

Papers cited by this study that are also in Blossom

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression

Sos, P., Klirova, M., Novák, T. et al. · Neuropsychiatric Disease And Treatment (2013)

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)

A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J. et al. · Bipolar Disorders (2014)

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

Murrough, J. W., Wan, L., Levitch, C. F. et al. · Journal of Clinical Psychiatry (2015)

Cited By (3)

Papers in Blossom that reference this study

Targeting glutamate signalling in depression: progress and prospects

Murrough, J. W., Abdallah, C. G., Mathew, S. J. · Nature Reviews Drug Discovery (2021)

Ketamine for treatment-resistant depression: recent developments and clinical applications

Schwartz, J., Murrough, J. W., Iosifescu, D. V. · Evidence-Based Mental Health (2016)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Towards new mechanisms: an update on therapeutics... — Research Summary & Context | Blossom